Table 1.
Response rates to neoadjuvant endocrine therapy regimens in early stage ER+ breast cancer
| Author year | # pts | Tumor stage | Menopause status | Regimen | N | Therapy duration | Responding (%) |
Stable (%) |
Progressing (%) |
|---|---|---|---|---|---|---|---|---|---|
| Ellis (2011) | 349 | T2-4c, N0-3, M0 | Post | Anastrozole | 114 | 16–18w | 74.6 | 17.5 | 7.9 |
| Exemestane | 114 | 68.4 | 24.6 | 7 | |||||
| Letrozole | 121 | 78.5 | 16.5 | 5 | |||||
| Iwata (2019) | 295 | T1c-T2, cN0, M0 | Post | Letrozole | 295 | 24–28w | 45 | 51 | 4 |
| Smith (2005) | 282 | T1-4, N0-3, M0 | Pre and Post | Anastrozole | 94 | 3mo | 40.4 | 50 | 9.6 |
| Tamoxifen | 96 | 37.5 | 57.3 | 5.2 | |||||
| Combination | 92 | 43.5 | 51.1 | 5.4 | |||||
| Johnston (2019) | 279 | T2-T4, M0 | Post | Letrozole | 93 | 14–16w | 50 | 45 | 5 |
| Palbo + Let | 186 | 54 | 43 | 3 | |||||
| Allevi (2013) | 118 | T2-4, N0-1, M0 | Post | Letrozole | 40 | 4mo | 45 | 45 | 10 |
| 38 | 8mo | 87 | 10 | 3 | |||||
| 40 | 12mo | 95 | 5 | 0 | |||||
| Toi (2011) | 104 | T2-3, N0-1, M0 | Post | Exemestane | 104 | 6mo | 57 | 39 | 4 |
| Olson (2009) | 100 | T2-4, N0-2, M0 | Post | Letrozole | 100 | 16–24w | 62 | 26 | 12 |
| Akashi-Tanaka (2009) | 87 | T2-T4 | Post | Anastrozole | 48 | 4mo | 42.5 | 50.5 | 7 |
| Tamoxifen | 39 | ||||||||
| Fontein (2014) | 79 | T2-T4, N0-3, M0 | Post | Exemestane | 77 | 6mo | 65 | 30 | 5 |
| Ueno (2014) | 61 | T2-3, N0-2, M0 | Post | Exemestane | 61 | 6mo | 52.5 | 39.3 | 8.2 |
| Barnadas (2009) | 54 | T2-4c, N1-2, M0 | Post | Exemestane | 54 | 6mo | 61 | 35 | 4 |
Progression defined as 20–25% increase in tumor area or appearance of new lesions
Palbo Palbociclib, Let letrozole